CSBR Stock Overview
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States.
No risks detected for CSBR from our risk checks.
Champions Oncology Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$8.03|
|52 Week High||US$14.68|
|52 Week Low||US$7.75|
|1 Month Change||-0.74%|
|3 Month Change||-20.50%|
|1 Year Change||-28.56%|
|3 Year Change||-19.62%|
|5 Year Change||117.62%|
|Change since IPO||-33.08%|
Recent News & Updates
We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation
The underwhelming share price performance of Champions Oncology, Inc. ( NASDAQ:CSBR ) in the past three years would...
|CSBR||US Life Sciences||US Market|
Return vs Industry: CSBR underperformed the US Life Sciences industry which returned 9.6% over the past year.
Return vs Market: CSBR underperformed the US Market which returned 13.7% over the past year.
|CSBR Average Weekly Movement||6.4%|
|Life Sciences Industry Average Movement||8.7%|
|Market Average Movement||6.6%|
|10% most volatile stocks in US Market||15.9%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: CSBR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: CSBR's weekly volatility (6%) has been stable over the past year.
About the Company
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized cancer care based upon the implantation of human tumors in immune-deficient mice.
Champions Oncology Fundamentals Summary
|CSBR fundamental statistics|
Is CSBR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CSBR income statement (TTM)|
|Cost of Revenue||US$21.47m|
Last Reported Earnings
Oct 31, 2021
Next Earnings Date
|Earnings per share (EPS)||0.029|
|Net Profit Margin||0.88%|
How did CSBR perform over the long term?See historical performance and comparison
Is Champions Oncology undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CSBR ($8.03) is trading below our estimate of fair value ($29.44)
Significantly Below Fair Value: CSBR is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CSBR is poor value based on its PE Ratio (277.6x) compared to the US Life Sciences industry average (39.9x).
PE vs Market: CSBR is poor value based on its PE Ratio (277.6x) compared to the US market (17.4x).
Price to Earnings Growth Ratio
PEG Ratio: CSBR is poor value based on its PEG Ratio (2.2x)
Price to Book Ratio
PB vs Industry: CSBR is overvalued based on its PB Ratio (13.4x) compared to the US Life Sciences industry average (3.3x).
How is Champions Oncology forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CSBR's forecast earnings growth (126.7% per year) is above the savings rate (2%).
Earnings vs Market: CSBR's earnings (126.7% per year) are forecast to grow faster than the US market (13% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CSBR's revenue (17.2% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: CSBR's revenue (17.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CSBR's Return on Equity is forecast to be high in 3 years time
How has Champions Oncology performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CSBR has high quality earnings.
Growing Profit Margin: CSBR became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: CSBR has become profitable over the past 5 years, growing earnings by 59.9% per year.
Accelerating Growth: CSBR has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: CSBR has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (72.2%).
Return on Equity
High ROE: CSBR's Return on Equity (4.8%) is considered low.
How is Champions Oncology's financial position?
Financial Position Analysis
Short Term Liabilities: CSBR's short term assets ($13.7M) exceed its short term liabilities ($12.5M).
Long Term Liabilities: CSBR's short term assets ($13.7M) exceed its long term liabilities ($8.8M).
Debt to Equity History and Analysis
Debt Level: CSBR is debt free.
Reducing Debt: CSBR had no debt 5 years ago.
Debt Coverage: CSBR has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CSBR has no debt, therefore coverage of interest payments is not a concern.
What is Champions Oncology current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CSBR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CSBR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CSBR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CSBR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CSBR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ronnie Morris (55 yo)
Dr. Ronnie Morris, M.D. has been Chief Executive Officer at Champions Oncology, Inc. since January 31, 2017 and its President since 2021. Dr. Morris previously served as the President and a Director of Cha...
CEO Compensation Analysis
Compensation vs Market: Ronnie's total compensation ($USD775.00K) is above average for companies of similar size in the US market ($USD578.13K).
Compensation vs Earnings: Ronnie's compensation has been consistent with company performance over the past year.
Experienced Management: CSBR's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Experienced Board: CSBR's board of directors are seasoned and experienced ( 10.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Champions Oncology, Inc.'s employee growth, exchange listings and data sources
- Name: Champions Oncology, Inc.
- Ticker: CSBR
- Exchange: NasdaqCM
- Founded: 1985
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$108.525m
- Shares outstanding: 13.51m
- Website: https://www.championsoncology.com
Number of Employees
- Champions Oncology, Inc.
- One University Plaza
- Suite 307
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/16 23:07|
|End of Day Share Price||2022/01/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.